BR112015022398A8 - comprimido de ondansetrona e preparação farmacêutica embalada - Google Patents
comprimido de ondansetrona e preparação farmacêutica embalada Download PDFInfo
- Publication number
- BR112015022398A8 BR112015022398A8 BR112015022398A BR112015022398A BR112015022398A8 BR 112015022398 A8 BR112015022398 A8 BR 112015022398A8 BR 112015022398 A BR112015022398 A BR 112015022398A BR 112015022398 A BR112015022398 A BR 112015022398A BR 112015022398 A8 BR112015022398 A8 BR 112015022398A8
- Authority
- BR
- Brazil
- Prior art keywords
- drug
- amount
- antiemetic
- release
- dispersed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Abstract
"formas de dosagem sólidas de libe-ração estendida de antieméticos". forma de dosagem oral sólida incluindo um núcleo que compreende uma matriz de polímero não iônico, uma primeira quantidade de um primeiro fármaco antiemético ou de um sal farmaceuticamente aceitável deste disperso na matriz, e um sal disperso na matriz; um primeiro revestimento de selagem de uma matriz de polímero não iônico envolvendo o núcleo; e uma camada de liberação imediata do fármaco envolvendo o primeiro revestimento de selagem, em que a camada de liberação imediata do fármaco compreende um polímero não iônico e uma segunda quantidade de um segundo fármaco antiemético ou um sal farmaceuticamente aceitável deste disperso neste, em que a camada de fármaco é suficientemente projetada para liberar a segunda quantidade do fármaco antiemético durante um período de, pelo menos, 1 hora, em que a forma de dosagem oral sólida é suficientemente projetada para liberar a primeira quantidade do primeiro fármaco antiemético e a segunda quantidade do segundo fármaco antiemético durante um período mínimo de 16 horas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782395P | 2013-03-14 | 2013-03-14 | |
| US61/782,395 | 2013-03-14 | ||
| PCT/IB2014/001633 WO2014181195A2 (en) | 2013-03-14 | 2014-03-14 | Antiemetic extended release solid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112015022398A2 BR112015022398A2 (pt) | 2017-07-18 |
| BR112015022398A8 true BR112015022398A8 (pt) | 2019-11-26 |
| BR112015022398B1 BR112015022398B1 (pt) | 2022-01-11 |
Family
ID=51528070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022398-2A BR112015022398B1 (pt) | 2013-03-14 | 2014-03-14 | Comprimido de ondansetrona e preparação farmacêutica embalada |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US9636305B2 (pt) |
| EP (1) | EP2983664B1 (pt) |
| JP (1) | JP6282676B2 (pt) |
| KR (1) | KR102270521B1 (pt) |
| CN (2) | CN112274489A (pt) |
| AU (1) | AU2014264342B2 (pt) |
| BR (1) | BR112015022398B1 (pt) |
| CA (1) | CA2905553C (pt) |
| CL (1) | CL2015002666A1 (pt) |
| ES (1) | ES2946985T3 (pt) |
| HK (1) | HK1223012A1 (pt) |
| IL (1) | IL241580B (pt) |
| MX (1) | MX2015012970A (pt) |
| NZ (1) | NZ712159A (pt) |
| PH (1) | PH12015502093A1 (pt) |
| RU (1) | RU2679448C2 (pt) |
| SG (1) | SG11201507450TA (pt) |
| WO (2) | WO2014181195A2 (pt) |
| ZA (1) | ZA201506961B (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015022398B1 (pt) | 2013-03-14 | 2022-01-11 | Redhill Biopharma Ltd | Comprimido de ondansetrona e preparação farmacêutica embalada |
| RU2706708C2 (ru) * | 2014-03-11 | 2019-11-20 | Редхилл Байофарма Лтд. | Твердые лекарственные формы ондансетрона с пролонгированным высвобождением для лечения симптомов тошноты, рвоты и диареи |
| CA2910865C (en) | 2014-07-15 | 2016-11-29 | Isa Odidi | Compositions and methods for reducing overdose |
| KR102300335B1 (ko) * | 2018-10-19 | 2021-09-10 | 주식회사 삼양홀딩스 | 아프레피탄트의 경구용 조성물 |
| US11969416B1 (en) * | 2022-11-03 | 2024-04-30 | Lumos Pharma, Inc. | Compactable oral formulations of ibutamoren |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4720353A (en) * | 1987-04-14 | 1988-01-19 | Richardson-Vicks Inc. | Stable pharmaceutical w/o emulsion composition |
| US6090411A (en) * | 1998-03-09 | 2000-07-18 | Temple University | Monolithic tablet for controlled drug release |
| US6733789B1 (en) * | 1999-01-21 | 2004-05-11 | Biovail Laboratories, Inc. | Multiparticulate bisoprolol formulation |
| JP2003516345A (ja) * | 1999-12-09 | 2003-05-13 | アルザ・コーポレーション | 抗ウイルス剤 |
| US6936275B2 (en) | 1999-12-20 | 2005-08-30 | Scolr, Inc. | Amino acid modulated extended release dosage form |
| WO2003024427A1 (en) | 1999-12-20 | 2003-03-27 | Temple University Of The Commonwealth System Of Higher Education | Tableted oral extended release dosage form |
| US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| US6500457B1 (en) | 2000-08-14 | 2002-12-31 | Peirce Management, Llc | Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent |
| US20020172712A1 (en) | 2001-03-19 | 2002-11-21 | Alan Drizen | Antiemetic, anti-motion sustained release drug delivery system |
| GB0119012D0 (en) | 2001-08-03 | 2001-09-26 | Strakan Group Plc | Transdermal delivery of drugs |
| GB0129489D0 (en) * | 2001-12-10 | 2002-01-30 | Quadrant Healthcare Uk Ltd | Sustained-release compositions |
| US20050131045A1 (en) * | 2002-04-30 | 2005-06-16 | Judith Aronhime | Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them |
| US7704527B2 (en) * | 2002-10-25 | 2010-04-27 | Collegium Pharmaceutical, Inc. | Modified release compositions of milnacipran |
| ATE359079T1 (de) | 2003-01-13 | 2007-05-15 | Dynogen Pharmaceuticals Inc | Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus |
| WO2005046700A1 (ja) | 2003-11-14 | 2005-05-26 | Senju Pharmaceutical Co., Ltd. | アミノグリコシド系抗生物質およびブロムフェナクを含有する水溶液製剤 |
| AU2005237360B2 (en) * | 2004-04-30 | 2010-10-21 | Astellas Pharma Inc. | Time-limited release type granular pharmaceutical composition for oral administration and intraoral rapid disintegration tablet containing the composition |
| JP2008524332A (ja) * | 2004-12-20 | 2008-07-10 | コレジウム ファーマシューティカル， インク． | 睡眠傷害のための医薬組成物 |
| CA2635313C (en) | 2005-12-29 | 2013-12-31 | Osmotica Corp. | Triple combination release multi-layered tablet |
| US20070190141A1 (en) | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
| US20080004260A1 (en) | 2006-06-29 | 2008-01-03 | Transcept Pharmaceuticals, Inc. | Compositions of 5-HT3 antagonists and dopamine D2 antagonists for treatment of dopamine-associated chronic conditions |
| ATE553754T1 (de) * | 2006-08-18 | 2012-05-15 | Evonik Roehm Gmbh | Pharmazeutische zusammensetzung mit kontrollierter wirkstoffabgabe für wirkstoffe mit guter löslichkeit in wasser |
| CN100584319C (zh) | 2006-10-16 | 2010-01-27 | 北京科信必成医药科技发展有限公司 | 群孔释放渗透泵控释片及其制备方法 |
| MX2009004439A (es) | 2006-10-25 | 2009-05-11 | Mcneil Ppc Inc | Composicion de ibuprofeno. |
| GB0624087D0 (en) | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| JP2010514679A (ja) | 2006-12-22 | 2010-05-06 | スリーエム イノベイティブ プロパティズ カンパニー | 制御放出組成物及び方法 |
| WO2009118763A1 (en) | 2008-03-28 | 2009-10-01 | Panacea Biotec Limited | Multilayered pharmaceutical compositions and processes thereof |
| US20100196291A1 (en) | 2009-01-30 | 2010-08-05 | Laurence Halimi | Personal care sunscreen compositions having reduced eye irritation |
| EP2403487A2 (en) | 2009-03-04 | 2012-01-11 | Fdc Limited | Oral controlled release dosage forms for water soluble drugs |
| US20110003005A1 (en) | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| RU2427389C2 (ru) * | 2009-10-09 | 2011-08-27 | Александр Владимирович Диковский | Фармацевтическая композиция для профилактики и лечения инфекционных и неинфекционных диарей |
| EP2506714A4 (en) * | 2009-11-30 | 2013-07-03 | Aptalis Pharmatech Inc | MOUTH ONDANSETRON TABLET COMPOSITIONS TO PREVENT EVIL AND CRUSH |
| BR112012015282A2 (pt) * | 2009-12-22 | 2016-03-15 | Abbott Healthcare Private Ltd | composição farmacêutica de liberação controlada |
| JP2013515782A (ja) | 2009-12-28 | 2013-05-09 | モノソル アールエックス リミテッド ライアビリティ カンパニー | オンダンセトロンを含む経口投与可能なフィルム製剤 |
| US8916194B2 (en) | 2010-08-30 | 2014-12-23 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| US20120128730A1 (en) * | 2010-11-23 | 2012-05-24 | Nipun Davar | Compositions and methods for once-daily treatment of obsessive compulsive disorder with ondansetron |
| BR112015022398B1 (pt) | 2013-03-14 | 2022-01-11 | Redhill Biopharma Ltd | Comprimido de ondansetrona e preparação farmacêutica embalada |
-
2014
- 2014-03-14 BR BR112015022398-2A patent/BR112015022398B1/pt active IP Right Grant
- 2014-03-14 KR KR1020157028825A patent/KR102270521B1/ko active IP Right Grant
- 2014-03-14 EP EP14795266.7A patent/EP2983664B1/en active Active
- 2014-03-14 AU AU2014264342A patent/AU2014264342B2/en active Active
- 2014-03-14 NZ NZ712159A patent/NZ712159A/en not_active IP Right Cessation
- 2014-03-14 WO PCT/IB2014/001633 patent/WO2014181195A2/en active Application Filing
- 2014-03-14 WO PCT/IB2014/001589 patent/WO2014184662A2/en active Application Filing
- 2014-03-14 ES ES14795266T patent/ES2946985T3/es active Active
- 2014-03-14 JP JP2015562425A patent/JP6282676B2/ja active Active
- 2014-03-14 SG SG11201507450TA patent/SG11201507450TA/en unknown
- 2014-03-14 CN CN202011222247.XA patent/CN112274489A/zh active Pending
- 2014-03-14 US US14/212,694 patent/US9636305B2/en active Active
- 2014-03-14 CN CN201480024401.9A patent/CN105530935A/zh active Pending
- 2014-03-14 RU RU2015143993A patent/RU2679448C2/ru active
- 2014-03-14 US US14/212,954 patent/US20140271851A1/en not_active Abandoned
- 2014-03-14 CA CA2905553A patent/CA2905553C/en active Active
- 2014-03-14 MX MX2015012970A patent/MX2015012970A/es unknown
-
2015
- 2015-09-10 IL IL241580A patent/IL241580B/en active IP Right Grant
- 2015-09-14 CL CL2015002666A patent/CL2015002666A1/es unknown
- 2015-09-14 PH PH12015502093A patent/PH12015502093A1/en unknown
- 2015-09-18 ZA ZA2015/06961A patent/ZA201506961B/en unknown
-
2016
- 2016-09-20 HK HK16111017.8A patent/HK1223012A1/zh unknown
-
2017
- 2017-03-22 US US15/466,214 patent/US20170189340A1/en not_active Abandoned
- 2017-08-16 US US15/678,386 patent/US20180028452A1/en not_active Abandoned
-
2020
- 2020-07-01 US US16/918,538 patent/US20200330392A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022398A8 (pt) | comprimido de ondansetrona e preparação farmacêutica embalada | |
| BR112018076601A2 (pt) | formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| BR112013008005A2 (pt) | composição farmacêutica kpiquida pronta para uso para adminidtração parental a um indivíduo | |
| AR077199A1 (es) | Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia | |
| DOP2015000183A (es) | Formulaciones farmacéuticas resistentes a la manipulación indebida | |
| HRP20191489T1 (hr) | Kombinirani sastav | |
| BR112013009153A2 (pt) | formulação de ligante de fosfato para dosagem única. | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| BR112017008993A2 (pt) | métodos e composições especificamente para o tratamento de transtorno de déficit de atenção | |
| BR112014014795A2 (pt) | sistema de pélete de multiunidade de liberação imediata | |
| CL2012001940A1 (es) | Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple. | |
| CO7111317A2 (es) | Método para el tratamiento de enfermedades ginecológicas | |
| AR098832A1 (es) | Uso de laquinimod para retrasar la progresión de la enfermedad de huntington | |
| PE20151543A1 (es) | Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso | |
| HRP20180620T1 (hr) | Liječenje napadaja vrućine tijekom menopauze ropinirolom i tizanidinom | |
| CU20130016A7 (es) | Composición farmacéutica de liberación prolongada de trimetazidina | |
| CO2022014548A2 (es) | Forma de dosificación oral sólida que comprende pomalidomida | |
| PH12016501756B1 (en) | Ondansetron extended release solid dosage forms for treating either nausea, vomiting or diarrhea symptoms | |
| CO7170180A2 (es) | Composición farmacéutica inyectable de dexketoprofeno y tramadol | |
| CL2016002655A1 (es) | Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol | |
| ECSP16005208A (es) | Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación | |
| BRPI1010987B8 (pt) | composições de dosagem sólida de liberação controlada contendo ibuprofeno | |
| Pérez | Revisión del tratamiento farmacológico de la urolitiasis | |
| BR112015016304A8 (pt) | formulações de liberação prolongada de lorazepam |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS. |